Newsletter | July 15, 2020

07.15.20 -- Updates From Thermo Fisher Scientific

 
NEWS FROM THERMO FISHER SCIENTIFIC
 
     
 
 
 
 
     
 
NEWS FROM THERMO FISHER SCIENTIFIC
     
COVID-19
 
Our Focus On Your Patients: COVID-19 And Beyond
 
 

Over the past several months we’ve been proud to partner with organizations across the life sciences ecosystem to deliver vaccines, antivirals, and treatments for COVID-19. These successes were enabled by more than $800M in investments in our network and delivered by our worldwide teams who pioneered solutions in the face of the toughest obstacles. Visit our COVID-19 Mobilization Page to learn more.

 
 
 
 
     
Partnerships
 
Partnering With CSL To Provide Best-In-Class Pharma Services
 
 

In a unique strategic partnership with CSL Behring, we’ll operate a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, when construction is completed in mid-2021. The site will feature highly flexible bioproduction technologies, including single-use and stainless steel, to provide a pathway from development to large-scale production. In addition to supporting CSL’s next-generation product for hemophilia patients, capacity will be available for additional biopharma customers. For more information, read our press release. You can also watch a video here.

 
 
 
 
     
Clinical Trials
 
Virtual Summit: Innovation In Clinical Trials Event — Now Available On Demand
 
 

Thermo Fisher Scientific brought together leaders from across the life sciences industry to share insights into the future of clinical trials. Innovative companies such as Accenture Life Sciences, Zipline International, and the Center for Information & Study on Clinical Research Participation came together to examine the most complex areas of trial management, such as patient engagement, integrating data and technology into clinical trials, and supply chain security.  All presentations are now available on demand.

 
 
 
 
     
Viral Vector Services
 
Fill/Finish And Regulatory Consulting Through Patheon Viral Vector Services
 
 

To continue to deliver on the needs of biopharma and research institutions, we’ve expanded our viral vector services portfolio to include fast, flexible fill/finish capabilities and regulatory consulting services. The comprehensive solution includes GMP and non-GMP fill/finish combined with regulatory expertise to enhance your process. For more information, download our Fill/Finish Services For Viral Vectors fact sheet and our viral vector services regulatory offering menu.